Every lot of GLP-2 / GLP-3 is tested by an independent ISO/IEC 17025-accredited lab in the USA. 99%+ purity isn't a target here. It's the requirement.
Don't take our word for it: test any vial at an accredited lab of your choice. If HPLC purity comes back under 99%, we refund your order and pay for the test.
This is a blend. GLP-2 and GLP-3 are combined in a single 20 mg vial, 10 mg of each. Both are multi-receptor incretin research compounds studied in metabolic models. GLP-2 is characterised at the GIP and GLP-1 receptors; GLP-3 adds glucagon-receptor activity to the same pair. Combining them in one vial is a formulation convenience for comparative work; the combination itself has not been characterised as a single entity.
The numbers that define GLP-2 / GLP-3 and how it is being studied. For laboratory research use only.
2
Research Compounds
GLP-2 · GLP-3
20 mg
Total Per Vial
10 mg of each component
3
Receptor Targets
GIP · GLP-1 · glucagon
4
Research Areas
Glucose handling
Energy balance
Lipid metabolism
How It Works
How GLP-2 / GLP-3 works
The pathways GLP-2 / GLP-3 acts on - and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
Dual Incretin Receptor Activity
GLP-2
GLP-2 is characterised as a co-agonist at the GIP and GLP-1 receptors. Insulinotropic signalling and gastric-emptying endpoints are the measured readouts in preclinical models.
GIP receptor engagement
GLP-1 receptor engagement
Glucose-dependent insulin release
Triple Receptor Activity
GLP-3
GLP-3 adds glucagon-receptor agonism to the GIP/GLP-1 pair. Energy-expenditure and hepatic-lipid endpoints are characterised alongside the incretin readouts.
Glucagon receptor engagement
Energy expenditure endpoints
Hepatic lipid measures
Comparative Conditions
Combined
Holding both compounds in one vial lets a protocol compare dual- and triple-receptor coverage under matched handling. No interaction between the two has been characterised.
Matched storage and handling
Comparative receptor coverage
Interaction not characterised
Uses & Applications
What GLP-2 / GLP-3 is researched for
The main areas GLP-2 / GLP-3 is being studied for - and the study-reported figures behind them.
Metabolic
Glucose Handling Models
Both compounds are studied for glucose-dependent insulin release in preclinical metabolic models.
Metabolic
Energy Balance
Energy-expenditure endpoints are characterised for the glucagon-receptor arm contributed by GLP-3.
Hepatology
Hepatic Lipid Measures
Hepatic lipid content is a recurring endpoint in triple-agonist literature.
Methods
Comparative Protocols
A single vial holding both compounds supports side-by-side receptor-coverage work under matched conditions.
Study-reported magnitudes
Representative figures from published research. Bars fill as you scroll.
GIP Receptor EngagementCharacterised
GLP-1 Receptor EngagementCharacterised
Glucagon Receptor (GLP-3)Characterised
Blend Interaction DataNone
Figures are representative of published research findings and shown for reference.
Molecular Structure
The GLP-2 / GLP-3 molecule
An interactive 3D model rendered from the compound record - rotate and explore its structure.
Molecular model
Sequence length
blend
Physical form
Lyophilized powder blend
Documented purity
≥99% by HPLC
Compound Information
Full specification
Components
GLP-2 + GLP-3
Content
20 mg per vial (10 mg of each component)
Receptor Targets
GIP · GLP-1 · glucagon
Form
Lyophilized powder blend
Purity
≥99% by HPLC
Appearance
White to off-white powder
Solubility
Water-soluble
Storage
-20°C, protected from light
Classification
Research use only
FAQ
Common questions about GLP-2 / GLP-3
The two cover different receptor sets. GLP-2 is characterised at the GIP and GLP-1 receptors; GLP-3 adds glucagon-receptor activity. Holding both in one vial supports comparative work under matched handling.
No. Each compound is characterised separately in the literature. The blend is a formulation convenience and no interaction data exists for the pair.
The separate products let you control each compound's quantity independently. This vial fixes the ratio at 10 mg and 10 mg.
Each lot is analysed by reverse-phase HPLC and released at ≥99%. A Certificate of Analysis accompanies the lot.
Store lyophilized at -20°C for long-term stability, protected from light and moisture, and avoid repeated freeze-thaw cycles.
Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
